2 3 Zenkuda in Retinal Vein Occlusion: Well-positioned to capture meaningful share in a large and growing >$3B RVO market • RVO is a meaningful and growing market 1. RVO market size from imarc: RVO Market Size, Epidemiology, In-Market drug sales, pipeline therapies, and Regional Outlook. 2. Regeneron earnings report. 3. Kalva, P et al. Baylor University Medical Center Proceedings , 36 (3), 335–340. 4. Based on data from the Phase 3 BEACON study in RVO. • ~3B estimated RVO market 1 ‒ ~20% of Eylea net sales derived from RVO in 2025 2 • ~1M people in the U.S. with RVO 3 ‒ Prevalence of RVO is growing globally, driven by growth in aging population • ~750,000 treatable with anti-VEGF • RVO is a chronic disease that requires long-term management • Despite acute onset, RVO often requires frequent long-term treatment • Approved intravitreal biologics require frequent injections that can be burdensome for patients and physicians Zenkuda is designed to address key unmet needs in RVO 4 6-month durability 75% of patients achieved 6-month durability at Year 1 in the Phase 3 BEACON study Strong efficacy Zenkuda doubled the treatment interval relative to aflibercept at month 6 (Q8W vs. Q4W) Fewer injections Potential to reduce treatment burden